Paving the way for T cell-based immunotherapies in chronic hepatitis E

Hepatitis E virus (HEV) causes an estimated 3 million cases of acute symptomatic hepatitis annually, which may have a severe course, leading to approximately 70,000 HEV-related deaths per year.1 Pregnant women are at the highest risk of a fulminant course upon infection with HEV genotypes 1 and 2, which are spread as waterborne pathogens in low-income regions. In middle- and high-income regions, severe courses of acute hepatitis E are usually observed in elderly people, following infection with the zoonotic HEV genotypes 3 and 4 that are transmitted by meat and less frequently by blood products.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Editorial Source Type: research